Cytel, a global leader in evidence generation and data-driven decision-making, announced a strategic partnership with Nested Knowledge to enhance its proprietary LiveSLR® platform with advanced AI capabilities. The collaboration, revealed on May 9, 2025, aims to create a fully auditable living evidence platform specifically designed for Health Economics and Outcomes Research (HEOR) and Health Technology Assessment (HTA).
The partnership integrates Nested Knowledge's AI-powered systematic literature review technology with Cytel's established methodology and domain expertise. This combination creates a unique offering in the field of evidence evaluation and synthesis, providing pharmaceutical companies with more efficient and comprehensive literature review capabilities.
Wyatt Gotbetter, Global Head of Cytel Evidence, Value and Access, emphasized the benefits for clients: "Cytel is excited to work with Nested Knowledge to ensure our clients can realize the advantages of our LiveSLR® and Nested Knowledge best-in-class offerings for their evidence and health economics needs. With LiveSLR® and Nested Knowledge software, our customers can feel confident we're employing the standard and get access to a set of differentiated deliverables to interact with their HEOR living evidence."
Key Technological Advantages
In an increasingly competitive systematic literature review (SLR) market, the enhanced LiveSLR® platform offers several distinct advantages:
- Best-in-class AI-enabled screening and extraction of relevant literature
- Automated generation of unlimited reports filtered by PICO (Population, Intervention, Comparison, Outcome) criteria
- Superior search strategies leveraging broad database access and domain expertise
- Industry-leading analytic and reporting capabilities specifically tailored for HTA and reimbursement decision-makers
These capabilities address critical challenges in the pharmaceutical industry, where timely access to comprehensive evidence synthesis can significantly impact market access strategies and reimbursement decisions.
Meeting Evolving Industry Demands
Keith Kallmes, President of Nested Knowledge, highlighted the strategic fit between the companies: "With their unique LiveSLR content offering, technically expert researchers, and nimble delivery model, Cytel's team integrates perfectly with health economists' complex workflows, allowing them to meet the changing demands for HTA-grade evidence in an evolving global pharmaceutical marketplace."
The collaboration comes at a time when pharmaceutical companies face increasing pressure to provide robust, transparent evidence to support value propositions for new therapies. Health technology assessment bodies worldwide are demanding more comprehensive and rigorous analyses to inform reimbursement decisions.
Impact on Evidence Synthesis Workflows
The enhanced LiveSLR® platform streamlines the traditionally labor-intensive process of systematic literature reviews. By automating screening and data extraction while maintaining human oversight, the solution reduces the time required to generate insights while preserving scientific rigor.
The platform's ability to generate "living" evidence libraries that update as new research emerges represents a significant advancement over traditional static reviews. This feature is particularly valuable in rapidly evolving therapeutic areas where new clinical evidence can quickly change the treatment landscape.
Broader Industry Context
This partnership reflects a growing trend toward AI-augmented workflows in pharmaceutical research and development. As the volume of published medical literature continues to expand exponentially, traditional manual review methods become increasingly impractical. AI-enhanced tools like the LiveSLR® platform enable more comprehensive evidence synthesis while reducing the resource burden.
For pharmaceutical companies navigating complex global markets, the ability to quickly adapt evidence packages for different regulatory and reimbursement environments represents a significant competitive advantage. The platform's capability to generate reports filtered by specific PICO criteria facilitates the global-to-local adaptation process that is essential for successful market access strategies.
The collaboration positions Cytel at the forefront of an evolving landscape in pharmaceutical evidence generation, offering life sciences innovators an AI-enabled solution designed to support strategic decision-making throughout the product lifecycle.
